ClinicalTrials.gg

Program

vecuronium

Also written as “Vecuronium” and “vecuronium bromide (0.1mg/kg)”.

Its studies are mostly in Arrhythmias, Cardiac, led by 2 companies.

Furthest: phase 4, since Nov 15, 20174 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck30 open or runningphase 4since Nov 15, 2017May 14, 2007none ahead
Amckaus PTY11 open or runningphase 2since Apr 20, 2026Apr 20, 2026Jun 30, 2027phase 2 · NCT07595393

Also a collaborator on its studies: novotech-australia-pty-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 14, 2007First study: phase 3 study in Anesthesia, GeneralNew to MerckMerck · NCT00473694 · 182 enrolled
  2. Oct 31, 2007Phase 2 study in Anesthesia, GeneralMerck · NCT00552617 · 100 enrolled
  3. Nov 15, 2017Phase 4 study in Arrhythmias, CardiacMerck · NCT03346057 · 344 enrolled · United States, Austria, Denmark and more
  4. Apr 20, 2026Amckaus PTY's first study: phase 2 study in Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia SurgeryNew to Amckaus PTYAmckaus PTY · NCT07595393 · 64 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia SurgeryAmckaus PTY · NCT07595393

TargetBeta

“Muscle-type nicotinic acetylcholine receptor antagonist”ChEMBL 37, by rule

Other programs on the same 5 targets

ProgramCompanyFurthest phaseStudies
RocuroniumruleMerckphase 411

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07595393Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery2Not yet recruitingAmckaus PTYJun 30, 202764
NCT03346057Arrhythmias, Cardiac · United States, Austria, Denmark and more4CompletedMerckSep 4, 2019344
NCT00552617Anesthesia, General2CompletedMerckAug 31, 2006100
NCT00473694Anesthesia, General3CompletedMerckNov 6, 2006182

How it is read

Names in the registry

  • “Vecuronium”, 2 entries
  • “vecuronium bromide (0.1mg/kg)”, 1 entry
  • “vecuronium”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.